共 47 条
[1]
Bruno R(2014)Evaluation of tumor-size response metrics to predict survival in oncology clinical trials Clin Pharmacol Ther 95 386-393
[2]
Mercier F(2015)Optimizing oncology therapeutics through quantitative clinical pharmacology: challenges and opportunities Clin Pharmacol Ther 97 37-54
[3]
Claret L(2015)Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials J Clin Oncol 33 36-41
[4]
Venkatakrishnan K(2015)Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 33 4-6
[5]
Friberg LE(2015)Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients Cancer Chemother Pharmacol 76 567-573
[6]
Ouellet D(2015)Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review Ann Oncol 26 485-496
[7]
Sharma MR(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
[8]
Gray E(2009)Overall survival and updated results for sunitinib compared with IFN-alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590
[9]
Goldberg RM(2013)Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 1287-1294
[10]
Venook AP(2013)Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomized double-blind phase 2 trial Lancet Oncol 14 1233-1242